文献速递慢性肾脏病

碳酸镧对3-4期慢性肾脏病患者血清钙蛋白颗粒的影响:一项安慰剂对照随机试验的结果

Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

IMPROVE-CKD试验的预设探索性分析纳入253例3b/4期慢性肾脏病患者,比较碳酸镧与安慰剂对血清钙蛋白颗粒(CPP)的影响。96周时,碳酸镧组与安慰剂组CPP-I和CPP-II均无显著差异,且CPP与脉搏波传导速度或腹主动脉钙化无相关性。

要点

  • 碳酸镧组与安慰剂组96周CPP-I变化无显著差异,组间差异22.8%(95%CI -39.2至36.4,P=0.65)。
  • 碳酸镧组与安慰剂组96周CPP-II变化无显著差异,组间差异-18.3%(95%CI -40.0至11.2,P=0.20)。
  • 血清CPP与基线脉搏波传导速度、腹主动脉钙化及其进展均无相关性。

核心结论

  • 在慢性肾脏病队列中,与安慰剂相比,碳酸镧治疗96周未伴随血清钙蛋白颗粒的降低。

研究设计与样本

  • IMPROVE-CKD为多中心、安慰剂对照、随机试验,评估碳酸镧对278例3b/4期慢性肾脏病患者心血管标志物的影响。
  • 本分析为预设探索性分析,在96周内测量亚组参与者的原发性和继发性钙蛋白颗粒。
  • 共253例参与者有基线和至少一个随访时间点的CPP数据并纳入分析,平均年龄62.4±12.6岁,女性占32.0%,平均eGFR为26.6±8.3 mL/min/1.73 m2。

主要发现

  • 基线血清CPP-I中位数为14.9×10^4颗粒/mL(IQR 4.6-49.3),CPP-II中位数为3.3×10^3颗粒/mL(IQR 1.4-5.4)。
  • 96周时,碳酸镧组与安慰剂组相比,CPP-I组间差异为22.8%(95%CI -39.2至36.4,P=0.65),无显著差异。
  • 96周时,碳酸镧组与安慰剂组相比,CPP-II组间差异为-18.3%(95%CI -40.0至11.2,P=0.20),无显著差异。
  • 血清CPP与基线脉搏波传导速度或腹主动脉钙化无相关性,与这两种标志物的进展也无相关性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calciprotein particles (CPP) are colloidal aggregates of calcium phosphate and the mineral-binding protein fetuin-A, and are potential mediators of cardiovascular disease in chronic kidney disease (CKD). Emerging evidence suggests non-calcium-containing phosphate binders may reduce serum CPP in patients with kidney failure who require dialysis; however, it is unclear whether similar interventions are effective in patients with earlier stages of CKD. METHODS: The IMpact of Phosphate Reduction On Vascular End-points in CKD (IMPROVE-CKD) was a multi-centre, placebo-controlled, randomized trial of lanthanum carbonate on cardiovascular markers in 278 participants with stage 3b/4 CKD. In this pre-specified exploratory analysis, primary (CPP-I) and secondary CPP (CPP-II) were measured in a sub-cohort of participants over 96 weeks. Treatment groups were compared using linear mixed-effects models and the relationship between serum CPP and pulse wave velocity (PWV) and abdominal aortic calcification (AAC) was examined. RESULTS: A total of 253 participants had CPP data for baseline and at least one follow-up timepoint and were included in this analysis. The mean age was 62.4 ± 12.6 years, 32.0% were female and the mean estimated glomerular filtration rate (eGFR) was 26.6 ± 8.3 mL/min/1.73 m2. Baseline median serum CPP-I was 14.9 × 104 particles/mL [interquartile range (IQR) 4.6-49.3] and median CPP-II was 3.3 × 103 particles/mL (IQR 1.4-5.4). There was no significant difference between treatment groups at 96 weeks in CPP-I [22.8% (95% confidence interval -39.2, 36.4), P = 0.65] or CPP-II [-18.3% (95% confidence interval -40.0, 11.2), P = 0.20] compared with a placebo. Serum CPP were not correlated with baseline PWV or AAC, or with the progression of either marker. CONCLUSIONS: Lanthanum carbonate was not associated with a reduction of CPP at 96 weeks when compared with a placebo in a CKD cohort.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Tiong MK, Smith ER, Pascoe EM, et al. Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial. Nephrol Dial Transplant. 2023. PMID: 35212735. doi:10.1093/ndt/gfac043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。